-
公开(公告)号：US08785605B2
公开(公告)日：2014-07-22
申请号：US13075241
申请日：2011-03-30
申请人： Juan Carlos Almagro , Patrick Branigan , Colleen Kane , William Strohl , Susann Taudte , Mark Tornetta , John Wheeler
发明人： Juan Carlos Almagro , Patrick Branigan , Colleen Kane , William Strohl , Susann Taudte , Mark Tornetta , John Wheeler
IPC分类号： C07K16/24 , A61K9/19 , A61K39/395
CPC分类号： C07K16/244 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).
摘要翻译： 本发明涉及结合人IL-25的指定表位的靶结合成员（例如抗体）。 本发明还涉及包含一个或多个人源化抗体VL结构域序列并结合IL-25的靶结合成员（例如抗体）。 本发明还涉及包含结合IL-25的靶结合成员（例如，抗体），产生此类靶结合成员的方法，以及这些靶结合成员用于治疗或预防疾病和病症（例如，哮喘， 炎性肠病）。
-
公开(公告)号：US20110318353A1
公开(公告)日：2011-12-29
申请号：US13075241
申请日：2011-03-30
申请人： Juan Carlos Almagro , Patrick Branigan , Colleen Kane , William Strohl , Susann Taudte , Mark Tornetta , John Wheeler
发明人： Juan Carlos Almagro , Patrick Branigan , Colleen Kane , William Strohl , Susann Taudte , Mark Tornetta , John Wheeler
IPC分类号： A61K39/395 , C12N15/13 , C12N15/63 , A61P29/00 , C12N1/21 , C12P21/00 , C12P21/02 , A61P11/06 , C07K16/24 , C12N5/10
CPC分类号： C07K16/244 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).
摘要翻译： 本发明涉及结合人IL-25的指定表位的靶结合成员（例如抗体）。 本发明还涉及包含一个或多个人源化抗体VL结构域序列并结合IL-25的靶结合成员（例如，抗体）。 本发明还涉及包含结合IL-25的靶结合成员（例如，抗体），产生此类靶结合成员的方法，以及这些靶结合成员用于治疗或预防疾病和病症（例如，哮喘， 炎性肠病）。
-
公开(公告)号：US20110236390A1
公开(公告)日：2011-09-29
申请号：US12915445
申请日：2010-10-29
申请人： Juan Carlos Almagro , Daniela Della Ducata , Merle Elloso , Jinquan Luo , Thomas Malia , Michael Naso , Galina Obmolova , Robert Rauchenberger , Mark Rutz , Raymond Sweet , Susann Taudte , Bingyuan Wu , Sheng-Jiun Wu
发明人： Juan Carlos Almagro , Daniela Della Ducata , Merle Elloso , Jinquan Luo , Thomas Malia , Michael Naso , Galina Obmolova , Robert Rauchenberger , Mark Rutz , Raymond Sweet , Susann Taudte , Bingyuan Wu , Sheng-Jiun Wu
IPC分类号： A61K39/395 , C12N15/63 , C12N5/10 , C07K16/24 , C12N1/00 , C07H21/00 , C07K1/107 , A61P29/00 , A61P11/00 , A61P17/06 , A61P11/06 , A61P19/02
CPC分类号： C07K16/244 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要： Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
摘要翻译： 公开了白细胞介素-177（IL-17A）抗体拮抗剂，编码IL-17A抗体拮抗剂或其片段的多核苷酸，以及制备和使用前述物质的方法。
-
公开(公告)号：US08519107B2
公开(公告)日：2013-08-27
申请号：US12915445
申请日：2010-10-29
申请人： Juan Carlos Almagro , Daniela Della Ducata , Merle Elloso , Jinquan Luo , Thomas Malia , Michael Naso , Galina Obmolova , Robert Rauchenberger , Mark Rutz , Raymond Sweet , Susann Taudte , Bingyuan Wu , Sheng-Jiun Wu
发明人： Juan Carlos Almagro , Daniela Della Ducata , Merle Elloso , Jinquan Luo , Thomas Malia , Michael Naso , Galina Obmolova , Robert Rauchenberger , Mark Rutz , Raymond Sweet , Susann Taudte , Bingyuan Wu , Sheng-Jiun Wu
CPC分类号： C07K16/244 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要： Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
摘要翻译： 公开了白介素-17A（IL-17A）抗体拮抗剂，编码IL-17A抗体拮抗剂或其片段的多核苷酸，以及制备和使用前述物质的方法。
-
公开(公告)号：US20130189250A1
公开(公告)日：2013-07-25
申请号：US13803887
申请日：2013-03-14
申请人： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
发明人： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC分类号： C07K16/46
CPC分类号： C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
摘要翻译： 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
公开(公告)号：US20120237528A1
公开(公告)日：2012-09-20
申请号：US13398881
申请日：2012-02-17
申请人： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
发明人： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC分类号： A61K39/395 , C12N1/21 , C12N1/19 , C12N15/63 , C07K16/18 , C07H21/04 , A61P35/00 , A61P35/02 , A61P35/04 , A61P27/02 , A61P27/06 , A61P7/00 , A61P19/02 , A61P17/06 , A61P17/02 , A61P9/00 , A61P21/00 , A61P1/00 , A61P9/10 , C12N5/10
CPC分类号： C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
摘要翻译： 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
公开(公告)号：US08580714B2
公开(公告)日：2013-11-12
申请号：US12904549
申请日：2010-10-14
IPC分类号： C40B10/00
CPC分类号： C07K16/00 , C07K16/248 , C07K2317/21 , C07K2317/76 , C07K2317/92
摘要： The invention relates to methods of affinity maturing antibodies.
摘要翻译： 本发明涉及亲和力成熟抗体的方法。
-
公开(公告)号：US20120093833A1
公开(公告)日：2012-04-19
申请号：US13269976
申请日：2011-10-10
IPC分类号： C07K16/24 , C12N15/13 , C12N5/10 , C12P21/02 , A61P19/02 , A61P17/06 , A61P11/00 , A61P11/06 , A61P25/00 , A61P29/00 , A61P19/08 , A61P9/10 , A61P13/12 , A61P35/00 , A61K39/395
CPC分类号： C07K16/248 , A61K2039/505 , A61K2039/54 , C07H21/00 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N15/09
摘要： Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
摘要翻译： 能够中和制瘤素M生物功能的抗体和组合物可用于治疗与制瘤素M相关的疾病和病症，例如骨关节炎和特发性肺纤维化。
-
公开(公告)号：US08722044B2
公开(公告)日：2014-05-13
申请号：US13398881
申请日：2012-02-17
申请人： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
发明人： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC分类号： A61K39/395 , C07K16/36 , C07K16/28 , A61K39/00
CPC分类号： C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
摘要翻译： 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
公开(公告)号：US20100261620A1
公开(公告)日：2010-10-14
申请号：US12578803
申请日：2009-10-14
IPC分类号： C40B50/06
CPC分类号： C07K16/2803 , C07K16/244 , C07K16/461 , C07K2317/55 , C07K2317/56 , C07K2317/92
摘要： Methods of humanizing and affinity-maturing antibodies are disclosed.
摘要翻译： 公开了人源化和亲和力成熟抗体的方法。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.031 秒)
